News

Driven by our patient centric mission, Weatherden is active in promoting the biotechnology industry and enabling the clinician scientists and drug development leaders of tomorrow, investing its expertise to facilitate next generation therapies that will transform patient outcomes long into the future.”
– Duncan McHale, Co-Founder
Biotech due diligence services launched!

03 November 2020

We are incredibly excited to launch our new ‘Biotech Due Diligence Services’ in collaboration with Veramed.

With this unique partnering of capabilities across translational medicine, clinical development and biostatistics, our combined team of experts is able to conduct data driven due diligence to ensure the value of any potential acquisition or partnership you are considering is appropriate.

We have created a bespoke due diligence framework which adapts our work to suit your needs and enables us to thoroughly interrogate the scientific and clinical merits of the assets in question. We will leave no stone unturned and seek to highlight additional opportunities for the assets along the way.

https://www.veramed.co.uk/duediligence/

Houman Ashrafian speaks at J&J flagship event

23 September 2020

Weatherden co-founder Houman Ashrafian will speak on harnessing early innovation at a flagship virtual event organised by J&J Innovations. Next Wave in Immune Therapeutics: From suppression to re-balancing the immune system will cover state-of-the-art developments in immunology, bringing together entrepreneurs, start-ups, researchers, and scientists from across EMEA and beyond.

Registration is free.

https://immunetherapeutics.splashthat.com/sm/

‘Opportunity on your doorstep: A guide to investing in the UK biotech sector’ published

10 September 2020

Weatherden co-founder Houman Ashrafian and CEO Emma Tinsley has contributed to a new guide produced by the UK Bioindustry Association.

Opportunity on your doorstep: A guide to investing in the UK biotech sector, has been created to help investors from the biggest institutions down to individuals planning for their retirement to understand the sector, including its diverse business models, the R&D process and the risks and benefits. It shows the opportunity for investors to reap financial returns from investing in UK biotech as part of their Environmental, Social and Governance (ESG) strategy.

https://www.bioindustry.org/policy/invest-in-biotech.html

Image module
Sophie Baillie appointed Head of Finance and Operations

13 July 2020

We are very pleased to announce the appointment of @Sophie Baillie as Head of Finance and Operations. Sophie has a background in science and consulting, having previously worked in roles providing clients in the life sciences, healthcare and technology sectors with financial and operational advice. She trained as a chartered accountant and chartered tax adviser at KPMG and, prior to that, read chemistry at the University of Cambridge, where she was a member of the Duer Research Group.

Emma Tinsley, Chief Executive, said “I am delighted to welcome Sophie Baillie at a pivotal time for Weatherden. We have seen rapid growth over the first three years and are continuing to build on this success. Sophie’s commitment to a flexibility of approach and the highest level of client service fits well with our model. I am looking forward to working with Sophie over the coming years as we drive Weatherden forward.”

Sophie Baillie added “I am very excited to have joined Weatherden and look forward to supporting its work with new clients, streamlining operations and driving efficiencies across the company. I am eager to see what the next twelve months and beyond bring and to contribute to Weatherden’s mission of maximising value for clients as they seek to translate cutting edge science into novel therapeutics for patients.”

Duncan McHale speaks on ‘Biotechs and Startups – a Pharmaceutical Medicine Perspective’

29 June 2020

Weatherden co-founder, Duncan Mchale, is participating in the Faculty of Pharmaceutical Medicine’s Conversation Series next Wednesday.

This event will debate the issues and opportunities and look at practical solutions surrounding the challenges of working in a Biotech/Start-Up. Bringing together a panel of medical and non-medical leaders from start-up/biotech companies and venture capital organisations, the conversation aims to encompass many topics.

To book your place, visit https://www.fpm.org.uk/events/fpm-conversation-biotechs-startups-a-pharmaceutical-medicine-perspective/

Duncan McHale and Emma Tinsley present at the UK BioIndustry Association’s Leadership Summit

5 June 2020

We are excited to join the BioIndustry Association for their Life Science Leadership Summit, which brings together CEOs from across the industry for three days of informed debate.

Weatherden’s Duncan Mchale and Emma Tinsley are speaking on patient stratification in “Workshop 3: Enabling technologies for impactful discovery – the role of AI”. Led by Precisionlife, the workshop will discuss how AI benefits organisations in this space.

10:00 – 10:40 – Target Discovery/Validation
10:45 – 11:25 – Hit Discovery and Lead Optimisation
11:30 – 12:10 – Pre-Clinical Assays/Models
12:15 – 12:55 – Patient Stratification

Image module
Emma Tinsley appointed Chief Executive Officer

1 June 2020

We are thrilled to announce the appointment of Emma Tinsley as our Chief Executive Officer. Emma joined Weatherden as CFO from SV Health Investors shortly after it was founded by Prof Houman Ashrafian and Dr Duncan McHale in 2017. In the three years since, the company has grown substantially in size and footprint, supporting emerging and established biotechs through their early clinical development. Weatherden is differentiated by its focus on translation into patients, managing investment strategically and embedding operational excellence early in the development process.

Prior to SV, Emma was at KPMG, where she worked in the life sciences audit practice with global pharmaceutical clients and in the technical accounting consulting practice. She is a keen advocate for the biotech industry, advising multiple small companies pro bono and mentoring entrepreneurs, and is regularly engaged to advise on financing strategies and maximising value through pre-seed to Series A.

Questions?
Get in touch.

Biotech consulting
Sophie Baillie
[email protected]

Due diligence
Stuart McGuire
[email protected]

© 2020 Weatherden Limited • All Rights Reserved